



Press Release

January 26, 2026

C4U Corporation

New Patent Issued in China (Patent No. ZL2021 8 0009880.7)

C4U Corporation (“C4U”) is pleased to announce that the patent for the invention “METHOD FOR DETECTING SPECIFIC DNA IN A SAMPLE”, was issued in China on January 13, 2026 as Patent No. ZL2021 8 0009880.7.

This invention discovered that it is possible to detect the target DNA in the sample using, as an indication, a signal generated by the cleavage of the single-stranded probe DNA. By mixing a single-stranded probe DNA whose cleavage can be detected in a reaction system, CRISPR-Cas3 system and a sample, we could obtain fast and handy results of detection.

This invention has already been patented in Japan in 2021 as Patent No. 6940086, then [in the United States \(Patent No. 12460271\)](#) and Singapore (Patent No. 11202251335Y).

C4U will continue to strengthen its intellectual property portfolio with regard to CRISPR-Cas3 technology worldwide and accelerate its application in a wide range of fields, including pharmaceutical field.

About C4U Corporation

C4U is a privately held biotech company based in Osaka, Japan, and is focused on the development of safe and efficient gene therapies utilizing its proprietary next generation CRISPR-Cas3 gene editing platform. In comparison to the CRISPR-Cas9 platform, CRISPR-Cas3 presents the distinct benefits of: 1) no off-target by the higher selectivity of deletion site (improved safety); 2) efficient knockouts by the larger deletion of gene sequences; and 3) an entirely independent patent portfolio. C4U has been granted a worldwide exclusive license to CRISPR-Cas3 by the University of Osaka for use in eukaryotic cells thus simplifying sublicensing transactions which is in sharp contrast to the complex and heavily litigated CRISPR-Cas9 patent landscape.

<https://www.crispr4u.jp/en/>

Contact Information

C4U Corporation

Address : Yamadaoka 2-8, Suita, Osaka 565-0871, Japan

E-mail : info@crispr4u.com